| Literature DB >> 34429327 |
Julio A Aguirre-Ghiso1,2,3,4,5.
Abstract
The paradigm of metastasis has been significantly remodeled by the incorporation of cancer dormancy as a mechanism to explain long-term remission intervals followed by relapse. There is overall consensus on the potential impact of better understanding dormancy. Key cancer-cell autonomous and microenvironmental mechanisms might explain this biology and, in turn, the timing of metastasis. However, the approach and feasibility to apply this biology to clinical trials has been controversial. The discussion here provides insight into how these controversies are being resolved by the development of active clinical trials, thus bringing to reality opportunities to target cancer dormancy. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34429327 PMCID: PMC8562555 DOI: 10.1158/0008-5472.CAN-21-1407
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701